{"schema_version":"1","generated_at":"2026-11-01T19:55:24.168Z","data_as_of":"2026-10-29","url":"https://www.findmykol.com/kol/thomas-ciulla","json_url":"https://www.findmykol.com/kol/thomas-ciulla/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"thomas-ciulla","name":"Thomas Ciulla","credential":"MD","title":"Retina Physician, Board Member, Midwest Eye Institute","specialty":"Ophthalmology","specialty_raw":"Ophthalmology","therapeutic_area":"Ophthalmology","therapeutic_areas":["Ophthalmology"],"institution":"Midwest Eye Institute","institution_url":"https://www.findmykol.com/institution/midwest-eye-institute","city":"Carmel","state":"IN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1770585838","orcid":"0000-0001-5557-6777","openalex":"A5036246396"},"summary":"Thomas Ciulla is Retina Physician, Board Member, Midwest Eye Institute at Midwest Eye Institute. OpenAlex indexes 326 publications with 14,128 citations (h-index 63); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the FindMyKOL directory.","overview":{"text":"Thomas A. Ciulla, M.D., is Retina Physician, Board Member, Midwest Eye Institute. The public record shows 326 publications with 14,128 citations (h-index 63), centered on Retinal Diseases and Treatments, Ocular Diseases and Behçet’s Syndrome, Retinal and Macular Surgery. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 2 companies.","bullets":["Most recent indexed publication: 2026 · Genes","Top research focus: Retinal Diseases and Treatments","13 registered trials on ClinicalTrials.gov","Open Payments reporting from 2 companies"],"generated_at":"2026-11-01"},"focus":{"indications":[{"label":"Edema","therapeutic_area":"Cardiology","trials":8,"topics":0,"strength":24},{"label":"Macular Edema","therapeutic_area":"Ophthalmology","trials":8,"topics":0,"strength":24},{"label":"Dry Eye / Uveitis","therapeutic_area":"Ophthalmology","trials":4,"topics":0,"strength":12},{"label":"Uveitis","therapeutic_area":"Ophthalmology","trials":4,"topics":0,"strength":12},{"label":"Uveitis, Posterior","therapeutic_area":"Ophthalmology","trials":4,"topics":0,"strength":12},{"label":"Uveitis, Intermediate","therapeutic_area":"Ophthalmology","trials":4,"topics":0,"strength":12},{"label":"Panuveitis","therapeutic_area":"Ophthalmology","trials":4,"topics":0,"strength":12},{"label":"Retinal Vein Occlusion","therapeutic_area":"Ophthalmology","trials":4,"topics":0,"strength":12},{"label":"Uveitis, Anterior","therapeutic_area":"Ophthalmology","trials":3,"topics":0,"strength":9},{"label":"Diabetic Complications","therapeutic_area":"Endocrinology/Metabolic","trials":3,"topics":0,"strength":9},{"label":"Diabetic Retinopathy / DME","therapeutic_area":"Ophthalmology","trials":3,"topics":0,"strength":9},{"label":"Macular Degeneration (AMD)","therapeutic_area":"Ophthalmology","trials":1,"topics":1,"strength":4},{"label":"Histoplasmosis","therapeutic_area":"Infectious Disease","trials":1,"topics":0,"strength":3},{"label":"Glaucoma","therapeutic_area":"Ophthalmology","trials":0,"topics":1,"strength":1}],"research_topics":["Retinal Diseases and Treatments","Ocular Diseases and Behçet’s Syndrome","Retinal and Macular Surgery","Retinal Imaging and Analysis","Glaucoma and retinal disorders"],"drugs_studied":{"total":1,"shown":1,"withheld":0,"rows":[{"name":"Dextenza","generic":"Dexamethasone","trials":0,"payments":1,"publications":1,"mentions":2}]},"works_with":{"total":6,"shown":3,"withheld":3,"rows":[{"name":"Clearside Biomedical, Inc.","trials":10,"payments":0,"mentions":10},{"name":"Barnes Retina Institute","trials":1,"payments":0,"mentions":1},{"name":"Carl Zeiss Meditec USA, Inc.","trials":0,"payments":1,"mentions":1}]}},"scholarship":{"works_count":326,"cited_by_count":14128,"h_index":63,"i10_index":171,"pubmed_count":34,"latest_activity_year":2026,"citation_standing":{"top_percent":5,"cohort":"Ophthalmology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"trials":{"count":13,"shown":3,"withheld":10,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT03203447","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","phase":"PHASE3","status":"TERMINATED","role":"Investigator","sponsor":"Clearside Biomedical, Inc.","source_url":"https://clinicaltrials.gov/study/NCT03203447","trial_url":"https://www.findmykol.com/trial/NCT03203447"},{"nct":"NCT03126786","title":"Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema","phase":"PHASE2","status":"COMPLETED","role":"Investigator","sponsor":"Clearside Biomedical, Inc.","source_url":"https://clinicaltrials.gov/study/NCT03126786","trial_url":"https://www.findmykol.com/trial/NCT03126786"},{"nct":"NCT03097315","title":"Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis","phase":"PHASE3","status":"COMPLETED","role":"Investigator","sponsor":"Clearside Biomedical, Inc.","source_url":"https://clinicaltrials.gov/study/NCT03097315","trial_url":"https://www.findmykol.com/trial/NCT03097315"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":2022},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"Carl Zeiss Meditec USA, Inc.","program_year":2022,"amount_usd":16.91,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1770585838"},{"payer":"Ocular Therapeutix, Inc.","program_year":2021,"amount_usd":129.57,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1770585838"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1770585838","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Sensory organs","share_pct":58.2,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":36.4,"drugs":[{"name":"Prednisolone Acetate","share_pct":100}],"max_beneficiaries":null},{"class":"Prostaglandin Analog","setting":"prescribed","share_pct":21.8,"drugs":[{"name":"Latanoprost","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cardiovascular","share_pct":41.8,"classes_total":1,"classes":[{"class":"Beta blocker","setting":"prescribed","share_pct":41.8,"drugs":[{"name":"Timolol Maleate","share_pct":100}],"max_beneficiaries":15}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"publications":{"total":34,"shown":5,"withheld":29,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation.","year":2026,"journal":"Genes","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42074510/","status":"verified"},{"title":"Biological therapies at 25 years: from incremental advances to revolutionary transformations.","year":2026,"journal":"Expert opinion on biological therapy","types":["Editorial"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41581012/","status":"verified"},{"title":"Beyond the injection: delivery systems reshaping retinal disease management.","year":2025,"journal":"Expert opinion on pharmacotherapy","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40319468/","status":"verified"},{"title":"Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies.","year":2025,"journal":"Expert opinion on biological therapy","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40298278/","status":"verified"},{"title":"THREE-YEAR CLINICAL OUTCOMES IN GEOGRAPHIC ATROPHY: An Analysis of 18,712 Patient Eyes.","year":2025,"journal":"Retina (Philadelphia, Pa.)","types":["Journal Article","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39724670/","status":"verified"}],"most_cited":{"total":326,"shown":5,"withheld":321,"rows":[{"title":"Diabetic Retinopathy and Diabetic Macular Edema","year":2003,"cited_by_count":835,"type":"review","source_url":"https://doi.org/10.2337/diacare.26.9.2653"},{"title":"Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor","year":1997,"cited_by_count":661,"type":"article","source_url":"https://doi.org/10.2337/diab.46.9.1473"},{"title":"Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study","year":2010,"cited_by_count":531,"type":"article","source_url":"https://doi.org/10.1016/j.ophtha.2010.08.016"},{"title":"Bacterial endophthalmitis prophylaxis for cataract surgery","year":2002,"cited_by_count":486,"type":"review","source_url":"https://doi.org/10.1016/s0161-6420(01)00899-5"},{"title":"INTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION","year":2000,"cited_by_count":423,"type":"article","source_url":"https://doi.org/10.1097/00006982-200003000-00004"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Alon Harris","coauthored_works":67},{"name":"Brent A Siesky","coauthored_works":32},{"name":"Ronald P. Danis","coauthored_works":31}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"linkedin","url":"https://www.linkedin.com/in/thomas-ciulla-md-mba-86a5504","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"MBA (Indiana University, 2015)","source_url":"https://medicine.iu.edu/faculty/24921/ciulla-thomas","status":"verified","collected_at":"2026-11-01"},{"value":"M.D. (University of California, San Francisco, 1991)","source_url":"https://medicine.iu.edu/faculty/24921/ciulla-thomas","status":"verified","collected_at":"2026-11-01"},{"value":"Board certified, American Board of Ophthalmology","source_url":"https://medicine.iu.edu/faculty/24921/ciulla-thomas","status":"verified","collected_at":"2026-11-01"}]},"roles":{"total":8,"shown":3,"rows":[{"value":"Adjunct Clinical Professor of Ophthalmology, Indiana University School of Medicine","source_url":"https://medicine.iu.edu/faculty/24921/ciulla-thomas","status":"verified","collected_at":"2026-11-01"},{"value":"Chief Medical Officer, Clearside Biomedical","source_url":"https://medicine.iu.edu/faculty/24921/ciulla-thomas","status":"verified","collected_at":"2026-11-01"},{"value":"President and CEO, Ikarovec","source_url":"https://onenucleus.com/ikarovec-appoints-thomas-ciulla-md-mba-expert-ophthalmology-drug-development-president-and-ceo","status":"verified","collected_at":"2026-11-01"}]},"secondary_affiliations":{"total":2,"shown":2,"rows":[{"value":"Clinical Professor / Co-Director of Retina Service, Indiana University School of Medicine (past)","source_url":"https://orcid.org/0000-0001-5557-6777","status":"verified","collected_at":"2026-11-01"},{"value":"Viridian Therapeutics, Chief Medical Officer (past)","source_url":"https://orcid.org/0000-0001-5557-6777","status":"verified","collected_at":"2026-11-01"}]},"media":{"total":2,"shown":2,"rows":[{"value":"ASRS Retina Health for Life podcast episode 'Gene Therapy for Retinal Disease' with Dr. Timothy Murray","source_url":"https://feeds.buzzsprout.com/1288340/episodes/7517278-gene-therapy-for-retinal-disease","status":"provisional","collected_at":"2026-11-01"},{"value":"OIS Podcast 'KOLs Speak Out on the Future of Gene Therapy' (moderator)","source_url":"https://ois.net/kols-speak-out-on-the-future-of-gene-therapy-podcast/","status":"provisional","collected_at":"2026-11-01"}]}},"similar":[{"name":"Richard Burgett","slug":"richard-burgett","institution":"Midwest Eye Institute","specialty":"Ophthalmic Plastic and Reconstructive Surgery","url":"https://www.findmykol.com/kol/richard-burgett","json_url":"https://www.findmykol.com/kol/richard-burgett/profile.json"},{"name":"Emily Chew","slug":"emily-chew","institution":"National Eye Institute","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/emily-chew","json_url":"https://www.findmykol.com/kol/emily-chew/profile.json"},{"name":"Robert Weinreb","slug":"robert-weinreb","institution":"University of California San Diego","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/robert-weinreb","json_url":"https://www.findmykol.com/kol/robert-weinreb/profile.json"},{"name":"Harry Quigley","slug":"harry-quigley","institution":"Johns Hopkins University School of Medicine","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/harry-quigley","json_url":"https://www.findmykol.com/kol/harry-quigley/profile.json"},{"name":"Joel Schuman","slug":"joel-schuman","institution":"Wills Eye Hospital","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/joel-schuman","json_url":"https://www.findmykol.com/kol/joel-schuman/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":10,"publications":29,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-01"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-01"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2022","collected_at":"2026-11-01"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-01"}},"methodology_url":"https://www.findmykol.com/about#methodology"}